TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* After a first documented idiopathic proximal deep vein thrombosis and/or pulmonary embolism~* After at least 3 months of oral anticoagulation~* After written informed consent~Exclusion Criteria:~* If the Venous thromboembolism occurred:~* during pregnancy or puerperium~* after recent (i.e. within three months) fracture or plaster casting of a leg,~* after immobilization with confinement to bed for three consecutive days~* after surgery with general anesthesia lasting longer than 30 minutes~* Patients with:~* active cancer~* antiphospholipid antibody syndrome~* antithrombin deficiency~* serious liver disease or renal insufficiency (creatininemia \> 2 mg/dL),~* other indications for anticoagulation or contraindications for this treatment~* limited life expectation~* Patients who live too far from the clinical center

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ECOG Performance Status range of 0-2~* Histologically confirmed cutaneous metastatic melanoma of V600 E, K, D or R.~* May be systemic naïve or received up to two previous systemic treatment regimens for metastatic melanoma.~* Must be able to undergo MRI and have at least one measurable intracranial lesion for which specific criteria have to be met.~Exclusion Criteria:~* Prior treatment with any BRAF inhibitor or any mitogen-activated protein/extracellular signal-regulated kinase inhibitor.~* Anti-cancer therapy or investigational anti-cancer therapy or chemotherapy without delayed toxicity within treatment specific timeframe.~* Treatment with stereotactic radiosurgery or treatment with whole-brain radiation within treatment specific timeframe.~* Any presence of leptomeningeal disease or any parenchymal brain metastasis~* History of another malignancy, some exceptions may apply.~* A history or evidence of cardiovascular risk- specific criteria have to be met~* A history or current evidence/risk of retinal vein occlusion or retinal pigment epithelial detachment - specific criteria have to be met.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.
- Cohort B (Type: EXPERIMENTAL): Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
- Cohort C (Type: EXPERIMENTAL): Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
- Cohort D (Type: EXPERIMENTAL): Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Skills to Enhance Positive Affect in Suicidal Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* current hospital admission due to concern of suicide risk~* ability of patient to speak, read, and understand English sufficiently well to complete the procedures of the study~* living at home~Exclusion Criteria:~* active psychotic disorder~* cognitive deficits that preclude full understanding of study materials~* adolescents who have become wards of the state and do not intend to return to the home of their biological or adoptive parents

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Positive Affect Skills Training (Type: EXPERIMENTAL): Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
- Treatment as Usual (Type: ACTIVE_COMPARATOR): Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed diagnosis of one the following:~  * Acute myelogenous leukemia in CR1, ER1, CR2, ER2, CR3~ * Acute lymphocytic leukemia in CR1, ER1, CR2, ER2, CR3~ * Non-Hodgkin's lymphoma~ * Hodgkin's lymphoma~ * Multiple myeloma with no more than 12 months of prior alkylator based chemotherapy~ * Myelodysplastic syndrome (MDS)~ * Acute leukemia arising out of MDS~ * Primary resistant acute leukemia~ * Chronic myelomonocytic leukemia~ * Aplastic anemia (40 years of age and over)~ * Solid tumor malignancy (germ cell, sarcoma, breast, etc.)~ * Genetic disorders or inborn errors of metabolism as defined by preparative regimen protocol~ * Chronic myelogenous leukemia~* Must meet all inclusion criteria specified by the respective preparative regimen protocol~* No aplastic anemia under 40 years of age or myelofibrosis~PATIENT CHARACTERISTICS:~Age:~* 0.5 to 65~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior red blood cell or platelet transfusions from a sibling donor~Chemotherapy:~* Not specified~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First-line mCRC~* EGFR positive~* Bi-dimensional measurable index lesion~Exclusion Criteria:~* Previous exposure to EGFR-targeting therapy~* Previous oxaliplatin-based therapy~* Previous chemotherapy for colorectal cancer except adjuvant treatment with progression of disease documented \> 6 months after end of adjuvant treatment~* Radiotherapy~* Surgery~* Any other investigational drug in the 30 days before randomization~* Brain metastasis and/or leptomeningeal disease~* Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab Plus FOLFOX-4 (Type: EXPERIMENTAL): None
- FOLFOX-4 Alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-65 years (both inclusive)~* Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months~* Body mass index 18.0-28.0 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening~* Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)~* Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- IDeg (Type: EXPERIMENTAL): None
- IGlar (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or older~2. Able to provide informed consent~3. Hospitalized adult patients with pneumonia evidenced by chest X-ray or CT scan~4. Laboratory (RT-PCR) confirmed infection with 2019-nCoV or strongly suspected to be infected with SARS-COV2 with confirmation studies pending~5. And at least one of the following:~   1. Respiratory frequency ≥30/min~  2. Blood oxygen saturation ≤93% on RA~  3. Partial pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2) \<300~  4. Worsening of lung involvement, defined as an increase in number and/or extension of pulmonary areas of consolidation, need for increased FiO2 to maintain stable O2 saturation, or worsening O2 saturation of \>3% with stable FiO2~Exclusion Criteria:~1. Treatment with any TNFα inhibitor in the past 30 days~2. Known hypersensitivity to any TNFα inhibitor, murine proteins, or any component of the formulation~3. Presence of any of the following abnormal laboratory values at screening: absolute neutrophil count (ANC) less than 1000 mm3, hemoglobin \<8.0g/L, platelets \<50,000 per mm3, or AST or ALT greater than 5 x ULN~4. Known active or latent Hepatitis B~5. Known or suspected active tuberculosis (TB) or a history of incompletely treated or latent TB.~6. Pregnancy~7. Intubated for \>48hours~8. Patients with uncontrolled systemic bacterial or fungal infections (Patients with a history of positive bacterial or fungal cultures but on enrollment are on appropriate therapy with negative repeat cultures may be enrolled)~9. Serious co-morbidity, including:~   1. Myocardial infarction (within last month)~  2. Moderate or severe heart failure (New York Heart Association (NYHA) class III or IV)~  3. Acute stroke (within last month)~  4. Uncontrolled malignancy~  5. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. estimated glomerular filtration rate (eGFR) \< 30 ml /min/1.73 m\^2) at baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infliximab (Type: EXPERIMENTAL): All patients enrolled into this trial will be assigned to the Infliximab arm. Patients will be treated with infliximab on Day 1, and may be re-treated per protocol and at the discretion of the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Determining Metabolic Effects of Valproate and Antipsychotic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets DSM-IV criteria for schizophrenia, any type, treated with the same antipsychotic for at least 6 months~* No antipsychotic medication dose changes for 1 month, and no other medication changes for 1 month prior to study entry~Exclusion Criteria:~* Meets DSM-IV criteria for substance abuse within 3 months of study entry~* Involuntary legal status (as per Missouri law)~* Any serious medical disorder that may confound the assessment of relevant biologic measures or diagnosis, including: significant organ system dysfunction, metabolic diseases, type 1 or 2 diabetes mellitus, pregnancy, endocrine disease, coagulopathy, anemia, or acute infection~* Currently taking more than one antipsychotic medication~* Currently taking prescription medications (except certain psychotropic medications as discussed below), including oral contraceptive pills, any glucose lowering agent, lipid lowering agent, exogenous testosterone, recombinant human growth hormone, or any other endocrine agent that might confound substrate metabolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 50% of participants will receive placebo
- Experimental (Type: EXPERIMENTAL): 50% of participants will receive Depakote ER

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, With One Site, Open-label Not Controled Trial, for the Observation of Treatment With CIDOFOVIR 1%, 3 Nights Per Week, During 4 Weeks, of Anal Intraepithelial Neoplasia, High Level, in HIV+ Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
* Inclusion Criteria:~  1. Patients who have given informed consent in writing of the study before making any specific selection procedure for the study.~ 2. Adult patients (18 years) with documented HIV infection, with high-grade AIN demonstrated by biopsy, and have not received any prior treatment for Anal Intraepithelial Neoplasia in the last 12 weeks.~ 3. For women of childbearing potential, negative pregnancy test in urine screening visit. All women of childbearing age should continue effective contraception throughout the study treatment.~* Exclusion Criteria:~  1. Patients who have received previous treatment of Anal Intraepithelial Neoplasia (AIN) in the last 12 weeks. 2. Dermatoses in patients with anogenital area 3. Patients with a history of pre-invasive neoplasia associated with Human Papilloma Virus 4. Patients with a history of previous neoplasm, of any origin and location, in the past 5 years.~  5. Patients with a history of hematologic abnormalities, kidney or liver 6. Pregnant or breastfeeding women or women of childbearing age who do not wish to use adequate contraception at the discretion of the investigator.~  7. Any disease or condition of the patient which, in the opinion of the investigator, is not adequate patient participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cidofovir 1% (Type: EXPERIMENTAL): Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Anxiety and Stress in Primary Care Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Veteran seen in the Syracuse VA Medical Center primary care clinic in the past year~* Screen positive for current (past 2 weeks) clinically significant anxiety symptoms (8 on Generalized Anxiety Disorder-7)~Exclusion Criteria:~* Inability to communicate in English (as assessed by study staff)~* Report or demonstrate hearing impairment that would preclude telephone screening (as assessed by study staff)~* Inability to demonstrate informed consent~  * defined as not being able to comprehend the study description as assessed by study staff and/or not being able to answer the comprehension of consent questions~ * have a diagnosis of dementia or severe cognitive impairment (defined by primary care provider or self-report, or having a diagnosis in Problem List)~ * screen positive for cognitive impairment (3 or more errors on cognitive screener)~* Have a diagnosis of obsessive-compulsive disorder (OCD) or serious mental illness (SMI) in Problem List~  * i.e., psychotic disorders, bipolar disorder~* Have an encounter diagnosis of post-traumatic stress disorder (PTSD) within the past 2 years OR screen positive for PTSD (3 or more on PC-PTSD-5)~* Currently in psychotherapy/counseling for anxiety and/or depression, defined as any of the following within the past 30 days:~  * attending specialty mental health sessions \[excluding a single intake session\]~ * attending 2 or more Primary Care-Mental Health Integration sessions~ * Being hospitalized for mental health treatment~* Report severe depressive symptoms (20 or more on Patient Health Questionnaire-9)~* At imminent risk of suicide~  * defined as being identified as imminent risk based on study staff's suicide risk assessment \[verified by the PI\] and in need of intensive treatment~ * e.g., hospitalization\] to ensure safety~* Started or had dosage change in psychotropic medication for anxiety or depression in the past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brief anxiety intervention (Type: EXPERIMENTAL): Modular anxiety intervention designed for PC-MHI, up to six 30-minute sessions occurring approximately every 2 weeks, patients select modules of interest to them to complete, emphasis on psycho-education and cognitive-behavioral coping strategies for self-management
- Usual PC-MHI care (Type: ACTIVE_COMPARATOR): Appointment with PC-MHI provider at local primary care clinic, providers delivers whatever interventions they deem appropriate and collaboratively decides with patients whether and when to meet again as in routine PC-MHI care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures.~2. Patients who participated in trial ARGX-113-1704 and are eligible for roll over, as specified in the protocol.~Other more specific inclusion criteria are further defined in the protocol.~Exclusion Criteria:~1. Patients who discontinued early from trial ARGX-113-1704 or patients who discontinued early from randomized treatment for pregnancy or rescue reasons or an (S)AE that might jeopardize the safety of the patient in that trial.~2. Pregnant and lactating women, and those intending to become pregnant during the trial or within 90 days after the last dosing. Women or childbearing potential should have a negative urine pregnancy test at SEB.~3. Male patients who are sexually active and do not intend to use effective methods of contraception during the trial or within 90 days after the last dosing or male patients who plan to donate sperm during the trial or within 90 days after the last dosing.~4. Patients with known Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) seropositivity.~Other, more specific exclusion criteria are further defined in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARGX-113 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete